<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261065</url>
  </required_header>
  <id_info>
    <org_study_id>VA-CDA</org_study_id>
    <nct_id>NCT01261065</nct_id>
  </id_info>
  <brief_title>Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure</brief_title>
  <official_title>Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael E. DeBakey VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michael E. DeBakey VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall hypothesis of this application is that the improvement in LV ejection performance&#xD;
      following treatment with betablockers is due, at least in part, to improvement in intrinsic&#xD;
      myocardial contractility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immediate specific objectives of this application are two-fold: (1) to determine whether&#xD;
      the observed improvement in LV ejection performance is due to alterations in intrinsic&#xD;
      cardiac myocardial contractility and (2) to determine whether changes in LV contractile&#xD;
      reserve following an infusion of intravenous milrinone can be used to predict a salutary&#xD;
      response to beta-blockers. The immediate specific objectives of this proposal will be&#xD;
      addressed in the following two Specific Aims: In Specific Aim 1, we will determine whether&#xD;
      the observed improvement in LV ejection fraction following treatment with beta-blockers is&#xD;
      due to changes in intrinsic myocardial contractility, as opposed to changes in LV remodeling&#xD;
      (i.e. reduction in LV volume) or changes in LV loading conditions. Changes in LV function&#xD;
      will be evaluated using proven indexes, one an ejection phase index: the relation of&#xD;
      end-systolic stress (ESS) to the mean velocity of fiber shortening (VCF), considered a&#xD;
      relatively load independent measure of contractility. Changes in LV structure will be&#xD;
      evaluated using echocardiography. In Specific Aim 2, we will determine whether the salutary&#xD;
      response to beta-blockers can be predicted by measuring &quot;contractile reserve&quot;, defined as a&#xD;
      change in contractility determined by the relation of the mean velocity of fiber shortening&#xD;
      (VCF) to end-systolic stress (ESS) in response to intravenous milrinone infusion at the&#xD;
      cardiac catheterization lab prior to the institution of beta-blockade. The response to&#xD;
      treatment with beta-blockers will be assessed by measurement of LV ejection fraction and LV&#xD;
      end-diastolic volume by echocardiography after 6 months of treatment with beta-blockers, and&#xD;
      these measurements will be correlated with the respective changes in contractile reserve&#xD;
      measurement at baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Load independent measure of contractility: Left ventricular velocity of circumferential shortening to left ventricular end systolic stress ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Mean velocity of circumferential fiber shortening (VCF) will be derived as = Left Ventricular Fractional shortening / Ejection Time.Left ventricular (LV) end-systolic stress will be calculated as = ([1.35 × P × LV endsysolic diameter]/(4 × LV posterior wall thickness in systole × (1+LV posterior wall thickness in systole /LV endsysolic diameter)))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end diastolic and end systolic volumes, left ventricular end systolic stress, effective arterial elastance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol</intervention_name>
    <description>Patients with heart failure and LVEF &lt; 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight &gt; 80 kg.</description>
    <other_name>coreg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 years of age or older.&#xD;
&#xD;
          2. Man or nonpregnant women (only women who are postmenopausal, surgically sterile or&#xD;
             practicing an acceptable method of contraception)&#xD;
&#xD;
          3. Patients with dilated nonischemic cardiomyopathy with LVEF&lt; 35% and NYHA Class III-IVa&#xD;
             heart failure&#xD;
&#xD;
          4. Patients on standard stable medical therapy with Ace inhibitors (or hydralazine and&#xD;
             nitrates or Angiotensin II Receptor blockers if Ace-intolerant), diuretics and or&#xD;
             digoxin for at least 1 month prior to enrollment in the study.&#xD;
&#xD;
          5. Heart failure symptoms have to be present for at least 3 months&#xD;
&#xD;
          6. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ischemic heart disease documented by cardiac catheterization with any coronary&#xD;
             obstructive lesion &gt; 50% stenosis, history of myocardial infarction, coronary artery&#xD;
             bypass surgery , percutaneous coronary angioplasty or stenting&#xD;
&#xD;
          2. Uncorrected primary valvular disease, obstructive or restrictive cardiomyopathy.&#xD;
&#xD;
          3. Systolic blood pressure &gt;170 or &lt;85 mm Hg or diastolic blood pressure &gt;100 mm Hg;&#xD;
             heart rate &lt;50 bpm.&#xD;
&#xD;
          4. Sick sinus syndrome or advanced heart block (unless treated by a pacemaker),&#xD;
             symptomatic or sustained ventricular tachycardia not controlled by antiarrhythmic&#xD;
             drugs or an implantable defibrillator&#xD;
&#xD;
          5. Cor pulmonale, obstructive pulmonary disease requiring oral bronchodilator or steroid&#xD;
             therapy&#xD;
&#xD;
          6. Active malignancy, or a systemic or terminal disease that would limit physical&#xD;
             function or survival during the trial&#xD;
&#xD;
          7. Active and known drug or alcohol dependence or any factors that will interfere with&#xD;
             the study conduct or interpretation of results.&#xD;
&#xD;
          8. Clinically important hepatic or renal disease; or any condition other than heart&#xD;
             failure that could limit survival&#xD;
&#xD;
          9. Platelet count &lt;100 000 mm3 or white blood cell count &lt;3000 mm3, INR (international&#xD;
             normalized ratio) &gt;1.7&#xD;
&#xD;
         10. Current treatment with beta-blocker, beta-agonist, verapamil, chronic cyclic or&#xD;
             continuous inotropic therapy, or use of an investigational drug within 30 days of&#xD;
             entry into the challenge phase&#xD;
&#xD;
         11. History of drug sensitivity or adverse reactions to beta-blockers&#xD;
&#xD;
         12. Unwillingness to cooperate or give written informed consent, pregnant or lactating&#xD;
             women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biykem Bozkurt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michael E.DeBakey VA Medical Center, Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey Veterans Affairs Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>December 15, 2010</last_update_submitted>
  <last_update_submitted_qc>December 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Biykem Bozkurt , MD</name_title>
    <organization>Michael E. DeBakey VA Medical Center, Baylor College of Medicine</organization>
  </responsible_party>
  <keyword>beta blockers</keyword>
  <keyword>heart failure</keyword>
  <keyword>contractility</keyword>
  <keyword>remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

